Sign up
Log in
MARKET
CMMB
CMMB
Chemomab Therapeutics Ltd
NASDAQ
1.300
+0.110
+9.24%
Opening 10:19 07/26 EDT
OPEN
1.340
PREV CLOSE
1.190
HIGH
1.340
LOW
1.240
VOLUME
97.59K
TURNOVER
0
52 WEEK HIGH
1.580
52 WEEK LOW
0.4200
MARKET CAP
18.48M
P/E (TTM)
-0.0485
1D
5D
1M
3M
1Y
5Y
1D
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Chemomab had previously announced it was not in compliance with minimum bid price requirement. Company's closing bid price had been below $1.00 for more than 30 consecutive business days. Nasdaq confirmed on July 23, 2024 that Chemomab has regained compliance with Listing Rule 5550.
Benzinga · 14h ago
Chemomab Therapeutics regains compliance with Nasdaq
Seeking Alpha · 14h ago
CHEMOMAB THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Reuters · 14h ago
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
Chemomab Therapeutics Ltd. Released topline results from the Phase 2 SPRING trial assessing its monoclonal antibody, CM-101, in patients with primary sclerosing cholangitis. The drug showed significant improvement in liver stiffness. The company also announced a $10 million investment in public equity.
Benzinga · 1d ago
Chemomab falls on private placement despite mid-stage win for lead asset
Seeking Alpha · 1d ago
Chemomab’s CM-101 Shows Promise in PSC Trial
TipRanks · 1d ago
CHEMOMAB - EXPECTS PIPE TO EXTEND CASH RUNWAY THROUGH BEGINNING OF 2026
Reuters · 1d ago
BRIEF-Chemomab Therapeutics Announces Positive Phase 2 Trial Results
Chemomab Therapeutics Ltd announces positive Phase 2 trial results. Company says its CM-101 drug has shown positive results in a clinical trial. The drug is being developed to treat liver strain in patients with advanced liver cancer. Company says the drug is in phase 2 of the trial.
Reuters · 1d ago
About CMMB
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Webull offers Chemomab Therapeutics Ltd - ADR stock information, including NASDAQ: CMMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMMB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading CMMB stock methods without spending real money on the virtual paper trading platform.